# An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

> **NCT07234032** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Insmed Incorporated** · enrollment: 344 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07234032
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2031-01-22
- **Final completion:** 2031-01-22
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234032, "An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07234032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*